Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
Abroad (travel likely)RecruitingEARLY_PHASE1
Conditions
Hematopoietic and Lymphoid Cell Neoplasm · Steroid Refractory Graft Versus Host Disease
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
M D Anderson Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Partow Kebriaei, MD)
Study leads
Partow Kebriaei, MD
Principal Investigator
M.D. Anderson Cancer Center